The Oncotic Pressure Myth: Why RBCs Aren't the Fluid-Overload Fix You Think They Are

There was an attending I worked with as a fellow who had a habit. Patient looks fluid overloaded, hemoglobin is borderline-low-ish, reach for a unit of red cells. The logic, stated out loud more than once: it'll help pull some of that fluid back into the vessels. Oncotic pressure. It made physiologic sense in the moment, the way a lot of things in medicine make sense until you actually look up the numbers.

I looked up the numbers.

What oncotic pressure actually is

Oncotic pressure — colloid osmotic pressure, if you want the precise term — is the pressure exerted by large proteins suspended in plasma that can't easily cross the capillary wall. It's the force that keeps fluid inside your blood vessels instead of leaking into the interstitium. Normal human plasma runs around 25–28 mmHg of oncotic pressure, and the overwhelming majority of that comes from one protein: albumin. Not hemoglobin, not clotting factors, not globulins in any meaningful way. Albumin.

This matters because a unit of packed red blood cells is not albumin-rich plasma. It's red cells suspended in a small volume of additive solution with very little protein left in it. Whatever oncotic punch it has isn't coming from the cells themselves — red cells are too large to meaningfully contribute to a colloid osmotic gradient — and there isn't much plasma left to carry albumin along for the ride.

The numbers

A 2020 study directly measured colloid osmotic pressure across blood products and found packed red cells sit at about 1.9 mmHg. For comparison, fresh frozen plasma measures around 20.1 mmHg, and normal human plasma is roughly 25.4 mmHg. Platelets land somewhere in between, around 7.5 mmHg. Storage didn't change any of this — old units and fresh units had essentially the same low oncotic pressure.

The authors' own conclusion is worth sitting with: because RBC oncotic pressure is so low, pulling extra fluid into the vasculature ("third-spacing" fluid into the blood) is an unlikely mechanism behind transfusion-associated circulatory overload, one of the most feared complications of transfusion. In other words, the product my attending reached for to manage fluid overload doesn't have much oncotic pressure to offer. They're just not doing much osmotically, full stop.

Okay, but albumin must work, right?

This is where it gets more interesting than "RBCs don't work, use albumin instead." Because albumin — the actual oncotic heavyweight, the protein doing 75–80% of the work in normal plasma — doesn't have a clean track record either.

The 2026 Surviving Sepsis Campaign guidelines suggest using crystalloids alone over crystalloids with supplemental albumin for fluid resuscitation in adults with sepsis or septic shock, a conditional recommendation based on moderate-certainty evidence. The ALBIOS trial, the largest sepsis-specific study of its kind, found no difference in 28-day mortality between albumin-plus-crystalloid and crystalloid alone. The SAFE trial, comparing albumin to saline across a broad ICU population, found no overall mortality difference either — though subgroup analyses have repeatedly hinted at a possible benefit in septic shock and a signal of harm in traumatic brain injury. Cochrane's own position on albumin has flipped at least once over the decades as new trial data accumulated.

The guidelines do carve out two situations where supplemental albumin may still be reasonable: patients who've already received large volumes of crystalloid, and patients with cirrhosis. Outside of those, the oncotic theory and the clinical outcomes data aren't telling the same story.

Part of the disconnect may be mechanistic. Albumin's advantage is theoretically largest in a vessel wall that's behaving normally. In sepsis and other inflammatory states — exactly the conditions where clinicians are most tempted to reach for it — capillary permeability increases, and infused albumin can leak into the interstitium right along with crystalloid. Once albumin is outside the vessel, it pulls fluid outside the vessel with it, paradoxically worsening fluid overload.

Sitting with the gap

So here's where I land, and I want to be honest that it's not a clean place to land: neither RBCs nor albumin reliably produce the specific physiologic outcome — durable intravascular fluid retention — that you would predict. RBCs because there's barely any oncotic pressure to speak of. Albumin because the theoretical advantage gets diluted by capillary leak in exactly the patients where it's most often considered.

I don't think this means "never give albumin" or "never transfuse RBCs in fluid overload." There may be other legitimate reasons to transfuse a fluid-overloaded patient — symptomatic anemia doesn't go away just because someone's also volume overloaded, and the clinical picture is rarely just one variable. What I think this does mean is that "it'll help pull fluid back in" is doing a lot of work that the data doesn't actually support, for either product.

The harder version of this

"It physiologically makes sense" and "it has been measured to do that in patients" are two different claims, and a fair amount of practice in medicine quietly substitutes the first for the second. Oncotic pressure is real, measurable, and important. It's also not a license to assume that giving a product with theoretically favorable properties produces the clinical effect we're hoping for. Sometimes the most rigorous thing you can do with a comfortable physiologic story is go check whether it survived contact with a colloid osmometer.

References

1. Klanderman RB, et al. Colloid osmotic pressure of contemporary and novel transfusion products. Vox Sanguinis. 2020.